References
- Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580–637.
- Timsit JF, Perner A, Bakker J, et al. Year in review in intensive care medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med. 2015 Apr;41(4):575–588.
- Husabø G, Nilsen RM, Flaatten H, et al. Early diagnosis of sepsis in emergency departments, time to treatment, and association with mortality: an observational study. PLoS One. 2020;15(1):e0227652.
- Kadri SS, Rhee C, Strich JR, et al. Estimating ten-year trends in septic shock incidence and mortality in United States academic medical centers using clinical data. Chest. 2017 Feb;151(2):278–285.
- Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. Jama. 2014 Apr 2;311(13):1308–1316.
- Klompas M, Calandra T, Singer M. Antibiotics for Sepsis-Finding the Equilibrium. Jama. 2018 Oct 9;320(14):1433–1434.
- Flynn A, Chokkalingam Mani B, Mather PJ. Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev. 2010 Nov;15(6):605–611.
- Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008 Oct;8(10):776–787.
- Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr Opin Crit Care. 2011 Apr;17(2):153–159.
- Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol. 2013 Nov;18(4):387.
- van der Poll T, van de Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017 Jul;17(7):407–420.
- Dai Y, Liang Z, Li Y, et al. Circulating long noncoding RNAs as potential biomarkers of sepsis: a preliminary study. Genet Test Mol Biomarkers. 2017 Nov;21(11):649–657.
- Zhang TN, Li D, Xia J, et al. Non-coding RNA: a potential biomarker and therapeutic target for sepsis. Oncotarget. 2017 Oct 31;8(53):91765–91778.
- Liu X, Hong C. Downregulation of lncRNA TUG1 contributes to the development of sepsis-associated acute kidney injury via regulating miR-142-3p/sirtuin 1 axis and modulating NF-κB pathway. 2019 Mar 4.
- Wang J, Song J, Li Y, et al. Down-regulation of LncRNA CRNDE aggravates kidney injury via increasing MiR-181a-5p in sepsis. Int Immunopharmacol. 2020 Feb;79:105933.
- Zhang X, Cui Y, Ding X, et al. Analysis of mRNA‑lncRNA and mRNA‑lncRNA-pathway co‑expression networks based on WGCNA in developing pediatric sepsis. Bioengineered. 2021;12(1):1457–1470.
- Xie H, Chai H, Du X, et al. Overexpressing long non-coding RNA OIP5-AS1 ameliorates sepsis-induced lung injury in a rat model via regulating the miR-128-3p/Sirtuin-1 pathway. Bioengineered. 2021. DOI:10.1080/21655979.2021.1987132.